Literature DB >> 33539850

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.

Joseph R Stoll1, Laura Battle2, Andrea Moy2, Stephen W Dusza1, Jae H Park3, Martin S Tallman3, Justin Taylor3, Alina Markova4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33539850      PMCID： PMC9398188          DOI： 10.1016/j.jaad.2021.01.096

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   15.487


× No keyword cloud information.
  5 in total

1.  High-dose cytosine arabinoside-induced cutaneous reactions.

Authors:  P Cetkovská; K Pizinger; P Cetkovský
Journal:  J Eur Acad Dermatol Venereol       Date:  2002-09       Impact factor: 6.166

2.  Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs.

Authors:  Claire Marie Reyes-Habito; Ellen K Roh
Journal:  J Am Acad Dermatol       Date:  2014-08       Impact factor: 11.527

3.  Cytarabine-induced palmar-plantar erythema.

Authors:  I R Walker; W E Wilson; D N Sauder; A M Benger; G Browman
Journal:  Arch Dermatol       Date:  1985-10

4.  Generalized benign cutaneous reaction to cytarabine.

Authors:  Beth S Ruben; Wesley Y Yu; Fan Liu; Sam V Truong; Kevin C Wang; Lindy P Fox
Journal:  J Am Acad Dermatol       Date:  2015-08-29       Impact factor: 11.527

5.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Authors:  Jeffrey E Lancet; Geoffrey L Uy; Jorge E Cortes; Laura F Newell; Tara L Lin; Ellen K Ritchie; Robert K Stuart; Stephen A Strickland; Donna Hogge; Scott R Solomon; Richard M Stone; Dale L Bixby; Jonathan E Kolitz; Gary J Schiller; Matthew J Wieduwilt; Daniel H Ryan; Antje Hoering; Kamalika Banerjee; Michael Chiarella; Arthur C Louie; Bruno C Medeiros
Journal:  J Clin Oncol       Date:  2018-07-19       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.